Compare Anza Therapeutics vs Traversa Therapeutics
Customers evaluate the quality of Anza Therapeutics's products using the following success metrics.
Overview
Anza Therapeutics is based in United States
Anza Therapeutics is developing active immunotherapies for the treatment of infectious diseases and cancer. Anza's therapeutic agents are based on its proprietary live-attenuated and Killed But Metabolically Active (KBMA) Listeria platforms which can be engineered to express antigens specific to the disease being treated.
Traversa Therapeutics is 18 yrs old and is based in United States.
Traversa Therapeutics is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi anti-cancer therapeutics. The company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of platform delivery technology, as well as advancement of therapeutic programs for the treatment of leukemia and glioblastoma.
Demo Video
Leadership
David Cook (President)
Steven F. Dowdy (Founder)
Funding
Investors
Sofinnova Partners and Kleiner Perkins Caufield & Byers
Mesa Verde Venture Partners, Morningside Ventures
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because Anza Therapeutics has not claimed their profile.
Work for Anza Therapeutics? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Anza Therapeutics?
Claim your profile now.
Information not available because Traversa Therapeutics has not claimed their profile.
Work for Traversa Therapeutics? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Traversa Therapeutics?
Claim your profile now.